Moderna, Inc MRNA Stock Price, News, Quote & History

However, this week, the company got good news with a mention of mRNA vaccines at the Project Stargate announcement and a new contract with the European Union. Discover which analysts rank highest on predicting the price target of MRNA. Discover which analysts rank highest for MRNA overall weighted by direction, price target, and price movement. Earlier this month, Cal-Maine Foods (CALM), the biggest U.S. egg producer, said egg prices have continued to rise because of limits on production because of the bird flu outbreak. Shares of Moderna (MRNA) took off Tuesday when the biotech firm announced that the U.S. government has awarded it more than a half a billion dollars to develop a vaccine that can be used against bird flu. MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.

• According to 20 analysts, the average rating for MRNA stock is “Hold.” The 12-month stock price forecast is $76.35, which is an increase of 84.38% from the latest price.
• Moderna expects to receive 10 product approvals in the next three years and is focused on its pipeline and cutting costs.
• Compared to revenue of $5 billion and $9 billion in cash on the balance sheet, Moderna is an interesting opportunity for a turnaround bet at current prices.
• It is comprised of a descending (falling) upper trendline resistance capping bounces converging with a flat-bottom lower trendline that provides a floor on pullbacks.
• In fact, the share price is now only right around the same level as it was before the 2020 pandemic.

Analyst Price Targets

Ellison mentioned using AI to help rapidly develop new vaccines as a benefit of Project Stargate, which is investing upwards of $500 billion in AI infrastructure in the United States over the next few years. Investors took this as a positive sign for Moderna stock, 12 best crypto trading bot platforms to invest with especially given that it could be an AI beneficiary. If you can use AI to make custom vaccines and cures for cancer, that could be a tremendous value to society and Moderna’s business. The maker of vaccines, including the mRNA vaccine for COVID-19, is amid a 90% stock price downturn. In fact, the share price is now only right around the same level as it was before the 2020 pandemic.

We and our partners process data to provide:

Merck desperately needs Moderna’s mRNA-based Personal Cancer Vaccines (“PCVs”) to extend KEYTRUDA’s patent protection beyond 2028. Tuesday, Moderna Inc MRNA stock is trading higher with a session volume of 8.0 million as per data from Benzinga Pro. Eva Ados, ERshares COO and chief investment strategist, joins CNBC’s ‘Power Lunch’ to share outlooks on three stocks. CAMBRIDGE, Mass. & BRISBANE, Australia–(BUSINESS WIRE)–Vaxxas, a clinical-stage biotechnology company commercializing a novel high-density microarray patch (HD-MAP) vaccination platform, today annou…

Even with today’s roughly 5% increase, Moderna shares remain nearly 65% lower over the last year as COVID-19 vaccine sales slump. To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address.

Norovirus cases are on the rise this winter, with outbreaks already up more than 30% by Dece… The Agreement provides participating countries with the opportunity to diversify their mRNA COVID-19 vaccine supply and gain access to pre-filled syringe front-end web developer job description template vaccine formats CAMBRIDGE, MA / ACCESS Newswir…

Moderna Stock Plummets 17% on 2025 Sales Guidance Slash

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Moderna plunges, retail guidance, bitcoin falls: Market Minute

You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time. While Moderna currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys. MRNA formed a descending trendline comprised of a descending upper trendline resistance that started at $48.92, converging with a flat-bottom lower trendline support at $33.31. The triangle encompasses the 17% gap down on the lowered guidance.

• MRNA vaccine developer Moderna (MRNA) is climbing nearly 5% in early trading today after it was awarded about $590 million by the U.S. government’s Department of Health and Human Services (HHS) on Friday.
• After submitting your request, you will receive an activation email to the requested email address.
• Moderna’s stock tumbles after a disappointing outlook for revenue and the need to accelerate its cost-cutting plan.
• A breakdown triggers if the stock falls below the lower trendline support.
• It could benefit from AI developments and is trading at a cheap price.
• Tuesday, Moderna Inc MRNA stock is trading higher with a session volume of 8.0 million as per data from Benzinga Pro.

Moderna’s stock tumbles to post-COVID lows after revenue outlook disappoints

The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. On January 13, 2025, Moderna provided a business update and also lowered full-year 2025 forecasts below estimates. The company is prioritizing its portfolio to address respiratory viruses, rare diseases, oncology, and viruses where there is an unmet need (enabling quicker FDA approval). Fiscal 2025 revenues are expected to be between $1.5 billion to $2.5 billion versus $2.92 billion consensus analyst estimates. Moderna expects to reduce 2025 cash cost expenses by $1 billion and an additional $500 million in 2026. It expects to end 2025 with a cash balance of $6 billion.

Department of Health and Human Services was aimed at accelerating development of “mRNA-based pandemic influenza vaccines,” including mRNA-1018. Please bear with us as we address this and restore your personalized lists. HHS reported that it had provided the drug maker with the funds in java 9 certification myexamcloud order “to accelerate the development of mRNA-based pandemic influenza vaccines and enhance (its) mRNA platform capabilities.” Please bear with us as we address this and restore your personalised lists. The U.S. government has awarded Moderna $590 million to advance the late-stage development of its mRNA bird flu vaccine, as the country doubles down on efforts to tackle increasing infections in human… Moderna explained that it began Phase 1/2 testing of mRNA-1018 in 2023 in healthy adults aged 18 and up, including candidates against the H5 and H7 avian influenza viruses.